Want to see PBH full AI Analyst Report?
PBH Stock Chart & Stats
$58.13
-$0.15(-0.20%)
At close: 4:00 PM EST
$58.13
-$0.15(-0.20%)
Day’s Range― - ―
52-Week Range$42.62 - $77.45
Previous CloseN/A
Volume57.25K
Average Volume (3M)783.95K
Market Cap
$2.36B
Enterprise Value$3.81K
Total Cash (Recent Filing)$63.87M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)12.8
Beta0.30
Next Earnings
Jul 30, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.94
Shares Outstanding47,372,166
10 Day Avg. Volume630,153
30 Day Avg. Volume783,950
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$72.00Price Target Upside23.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)4.54
Revenue Forecast (FY)$1.19B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent, high free cash flow (~$230M–$260M historically) provides durable internal funding for M&A, buybacks, and debt paydown. Strong FCF conversion supports financial flexibility and reduces reliance on external financing, sustaining strategic options over the next 2–6 months.
Improving Balance Sheet / DeleveragingMaterial reductions in leverage and equity growth strengthen solvency and covenant headroom, enabling integration of acquisitions and capital returns. The step-change deleveraging increases resilience to shocks, though the drivers of the 2026 drop should be monitored for sustainability.
Margin Resilience And Low CapexStable mid-50s gross margins and low capital intensity underpin persistent high operating cash conversion and profitability. Low ongoing capex needs allow the company to sustain brand investment, marketing, and shareholder returns without eroding operating margins over the medium term.
Bears Say
Top-line WeaknessRecurrent flat-to-declining revenue trends limit the firm's ability to grow operating profit organically. With muted organic growth and a 2026 decline, sustaining margins and FCF growth will depend more on M&A and pricing, increasing execution dependency over the next several quarters.
Operational / Supply RiskProduction shutdowns and extended ramp timelines create persistent execution risk that can depress near-term sales and disturb retailer relationships. Repeated supply issues raise the chance of ongoing volatility in shipment timing and inventory, pressuring revenue for months while capacity normalizes.
Higher Near-term Leverage From AcquisitionsLarge, debt-funded deals increase secured borrowing and covenant reliance, raising leverage and refinancing risk in the near term. Even if accretive long term, the heavier debt load heightens sensitivity to integration execution and cash flow variability over the next 2–6 months.
Prestige Consumer Healthcare News
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $42.62 and its highest was $77.45 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.36B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on May 13, 2026. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by -$0.16.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 0.88.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,372,166 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.23 in its last earnings report, missing expectations of $1.39. Following the earnings report the stock price went down -11.349%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.00 (23.86% Upside)
$72.00 (23.86% Upside)
Blogger Sentiment
Neutral
PBH Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 815.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $225.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.66%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBH Stock 12 Month Forecast
Average Price Target
$72.00
▲(23.86% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.41% Insiders
46.33% Mutual Funds
0.75% Other Institutional Investors
23.02% Public Companies and
Individual Investors